Drug Type CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Lymphocytic Leukemia | Phase 2 | Germany | 07 Sep 2018 | |
Chronic lymphocytic leukaemia refractory | Phase 2 | Germany | 07 Sep 2018 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | Germany | 07 Sep 2018 | |
Follicular Lymphoma | Phase 2 | Germany | 07 Sep 2018 | |
Mantle-Cell Lymphoma | Phase 2 | Germany | 07 Sep 2018 |
Phase 1/2 | CD19+ | 3 | HD-CAR-1 | okbieibnia(ubqyjnslcx) = mghcrlipak dlkhkfuzga (dputwbuyzb ) | Positive | 24 Mar 2019 |